Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Gilead Sciences (NQ: GILD)
68.54 USD  -0.01 (-0.01%)
Streaming Delayed Price  /  Updated: 5:09 AM EST, Jan 23, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 150
Open 68.74
Bid (Size) 68.53 (1)
Ask (Size) 68.60 (1)
Prev. Close 68.55
Today's Range 68.02 - 68.82
52wk Range 60.32 - 89.54
Shares Outstanding 1,300,260,832
Dividend Yield 3.25%
Performance
YTD
+8.04%
+8.04%
1 Month
+13.21%
+13.21%
3 Month
-4.37%
-4.37%
6 Month
-11.73%
-11.73%
1 Year
-15.81%
-15.81%
Top News
More News
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes. At 4:30 p.m. Eastern... Read More
from Business Wire News Releases
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for... Read More
from Business Wire News Releases
More News
Read More
Notable Friday Option Activity: WYNN, GS, GILD
category Stocks
from Market News Video
Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year
category SRRK , Biopharmadrive , Steve Seedhouse , and 17 more.
from Benzinga
Better Buy: Biogen vs. Gilead Sciences
category BIIB , Market News , GILD
from Motley Fool
These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
from Investor's Business Daily
IXJ, TMO, CVS, GILD: Large Inflows Detected at ETF
category ETFs
from ETF Channel
1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet)
category CELG , ABBV , BMY , and 2 more.
from Motley Fool
Why Gilead Sciences Stock Sank by 12.7% in 2018
category GILD , Market News
from Motley Fool
REFILE-Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
category companyNews
from Reuters: Company News
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.